Can sorafenib cure cancer?
Sorafenib is a new multikinase inhibitor, which has been shown to exhibit a significant anticancer effect in the treatment of solid tumors. It has been approved for the treatment of advanced RCC, and was recently found to improve survival of patients with advanced HCC as compared to placebo when used as monotherapy.
What is sorafenib 200 mg used for?
Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
When was sorafenib approved for HCC?
The U.S. Food and Drug Administration (FDA) on November 19 announced that it has approved sorafenib (Nexavar) for use in patients with hepatocellular carcinoma (HCC) when the cancer is inoperable. Sorafenib was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma.
How to choose between sorafenib and lenvatinib?
The choice between sorafenib and lenvatinib should be taken considering the clinical setting, key inclusion/exclusion criteria of randomized trials, evidence coming from retrospective and prospective studies on special populations, safety profile and patient’s preferences.
What type of drug is sorafenib?
Sorafenib Sorafenib is a TKI targeting the RAF/MEK/ERK axis of the RAS cascade signal, vascular endothelial growth factor receptors (VEGFRs) 1–3 and the platelet-derived growth factor receptor β (PDGFR-β).13
How many clinical trials have been conducted on sorafenib for hepatocellular carcinoma?
The search was restricted to clinical trials in English language only and yielded 65 reports. Of these publications, 21 described the use of targeted drugs for treatment of hepatocellular carcinoma, 11 were studies of single-drug sorafenib treatment, and three were studies of sorafenib in combination with another drug.
How effective is sorafenib as a first-line treatment for multiple sclerosis (MS)?
Sorafenib, an oral multikinase inhibitor, is the only systemic therapy proven to extend overall survival when used as a first-line treatment, showing a median improvement of 2·8 months compared with placebo (10·7 months vs 7·9 months; hazard ratio [HR] 0·69; p<0·001), despite a low response rate of 2%.